Main Conference Day 3Friday, 29 May 2026 - European Time GMT+1

Systemic toxicities from target expression on healthy tissues limit cancer therapy. The PrimeBody platform employs protease-cleavable linkers and affinity-tuned masking to generate tumor-activated biologics with exceptional systemic stability and efficient tumor activation. VOR-101, a masked, Fc-enhanced CD47 blocker, remains inert in circulation but rapidly activates in tumors, achieving >700-fold selectivity. It delivers ~100-fold higher exposure than conventional agents without toxicity, driving durable tumor regressions and a markedly improved therapeutic index.

T cell engagers (TCEs) show promise in solid tumors but are constrained by cytokine release and on-target, off-tumor toxicity. Amberstone’s T-MATE™ platform overcomes these barriers with a pH-gated, target-selective mechanism that adapts to tumor pH heterogeneity while maintaining an optimal therapeutic profile. This conditional strategy enables a new generation of TCEs that combines both safety and efficacy with broad applicability across diverse solid tumor indications.

PRO-XTEN™ masked T cell engagers (TCEs) are conditionally activated immune therapeutics designed to exploit dysregulated protease activity within the tumor microenvironment. This approach enables tumor-selective TCE activation while minimizing systemic toxicity. The XTEN mask serves a dual function: masking TCE activity and extending the half-life of the masked molecule, while the proteolytically activated TCE exhibits a short half-life, creating conditional pharmacokinetics that enhance tumor exposure while limiting systemic active drug circulation. Preclinical studies demonstrated: (1) robust masking with ~10,000-fold reduction in cytotoxicity in vitro; (2) potent anti-tumor efficacy in vivo at doses comparable to unmasked TCE controls; and (3) >100-fold improvement in maximum tolerated dose (MTD) in non-human primates. These findings support a significantly enhanced therapeutic window through tumor-specific activation and conditional PK. Clinical trials evaluating PRO-XTEN™ TCEs targeting HER2, PSMA, and EGFR are currently underway, with early data demonstrating the translational potential of this protease-activated platform.